Suppr超能文献

益生菌作为哮喘患者辅助治疗的应用:一项初步研究及意义。

The use of probiotics as a supplementary therapy in the treatment of patients with asthma: a pilot study and implications.

机构信息

Programa de Pos Graduacao em Ciencias da Saude, Faculdade de Ciencias Medicas de Minas Gerais, Belo Horizonte, MG, BR.

Departamento de Pediatria, Universidade Federal de Minas Gerais, Belo Horizonte, MG, BR.

出版信息

Clinics (Sao Paulo). 2019;74:e950. doi: 10.6061/clinics/2019/e950. Epub 2019 Aug 12.

Abstract

OBJECTIVES

Evaluate the use of probiotics as an additional therapy in the treatment of children and adolescents with asthma in Belo Horizonte, MG-Brazil.

METHODS

A pilot longitudinal, experimental and nonrandomized study with 30 patients from six to 17 years old from Belo Horizonte. In the baseline appointment, all patients received beclomethasone, and one group also received a probiotic containing Lactobacillus reuteri (n=14). The patients were reassessed after at least 60 days with the Asthma Control Test, spirometry and self-report of the symptoms they experienced associated with asthma.

RESULTS

A predominance of male patients (56.7%) and a mean age of 10.6 years were observed. The groups using probiotics did not differ in terms of sex, age or atopy. In the longitudinal evaluation, an increase in the Asthma Control Test scores and a reduction in the number of symptoms were observed in the probiotic group. There was an increase in the peak expiratory flow among those who used probiotics.

CONCLUSIONS

This pilot study supports the hypothesis that the administration of probiotics as a supplementary therapy for the treatment of children and adolescents with asthma improves the clinical condition of the patients. Further studies are needed to confirm the efficacy of probiotics in asthma treatment.

摘要

目的

评估益生菌作为辅助疗法在巴西米纳斯吉拉斯州贝洛奥里藏特治疗儿童和青少年哮喘的应用。

方法

一项具有 30 名 6 至 17 岁患者的试点性、纵向、实验性和非随机研究。在基线就诊时,所有患者均接受了倍氯米松治疗,其中一组还接受了含有罗伊氏乳杆菌的益生菌治疗(n=14)。至少 60 天后,通过哮喘控制测试、肺量计和患者自我报告与哮喘相关的症状,对患者进行重新评估。

结果

观察到男性患者(56.7%)居多,平均年龄为 10.6 岁。使用益生菌的两组在性别、年龄或特应性方面没有差异。在纵向评估中,益生菌组的哮喘控制测试评分增加,症状数量减少。使用益生菌的患者中,呼气峰流速增加。

结论

这项初步研究支持了以下假设,即益生菌作为辅助疗法用于治疗儿童和青少年哮喘,可以改善患者的临床状况。需要进一步的研究来证实益生菌在哮喘治疗中的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d99/6683305/6abe03225756/cln-74-e950-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验